.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

DermView: Innovations in the Treatment of Vitiligo

Expert dermatologists provide an overview of vitiligo while reviewing presentation, diagnosis, and the goals of therapy related to current and future therapies.

EP. 1: An Overview of Vitiligo

November 23rd 2021

Expert dermatologists Seemal Desai, MD, FAAD, and William Damsky, MD, PhD, provide an overview of vitiligo, as an autoimmune disorder, and its prevalence.

EP. 2: Understanding the Psychosocial Impact of Vitiligo

November 23rd 2021

Shared insight on the psychological and social impact of vitiligo, along with practical advice on how to communicate with and support patients.

EP. 3: Vitiligo: Clinical Presentations and Classifications

November 30th 2021

A comprehensive breakdown of the different classifications of vitiligo and how these may present clinically.

EP. 4: Diagnosing Vitiligo and Improving Care Provider Awareness

November 30th 2021

Expert perspectives on the diagnosis of vitiligo and considerations for improving provider awareness in dermatologist and community settings.

EP. 5: Vitiligo: Managing Patient Motivation and Expectations for Treatment

December 7th 2021

Seemal Desai, MD, FAAD, and William Damsky, MD, PhD, discuss methods for managing a patient’s motivation and expectations when on therapy for vitiligo.

EP. 6: Treatment for Vitiligo: Options and Unmet Needs

December 7th 2021

A brief review of the treatment armamentarium for vitiligo, as well as the prevalent unmet needs in that setting.

EP. 7: Novel Therapy in Vitiligo: Topical JAK Inhibitors

December 14th 2021

Shared insight from dermatologists on novel topical JAK inhibitor therapy being investigated as an option for patients with vitiligo.

EP. 8: Looking Toward the Future Management of Vitiligo

December 14th 2021

Looking toward the future management of vitiligo, expert dermatologists close out their discussion on JAK inhibition and other novel therapy.